Scribe Therapeutics (SCTX)
Market Price (10/9/2026): $20.14 | Market Cap: $325.9 MilSector: Health Care | Industry: Biotechnology
Scribe Therapeutics (SCTX)
Market Price (10/9/2026): $20.14Market Cap: $325.9 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -47%, 3Y Excs Rtn is -95% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -39 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -149% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -127%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -130% High stock price volatilityVol 12M is 139% Key risksSCTX key risks include [1] potential failure of its lead candidate, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -47%, 3Y Excs Rtn is -95% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -39 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -149% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -127%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -130% |
| High stock price volatilityVol 12M is 139% |
| Key risksSCTX key risks include [1] potential failure of its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Scribe Therapeutics (SCTX) stock has lost about 10% since it went public on 7/24/2026 because of the following key factors:
1. Post-IPO Price Correction Following Initial Enthusiasm.
Scribe Therapeutics (SCTX) debuted on July 24, 2026, with its stock opening at $25.00 and closing its first trading day at $21.65, representing a significant 44.33% gain from its IPO price of $15.00 per share. However, newly public stocks often experience a period of price correction after initial investor excitement. From its closing price on July 24, 2026, the stock subsequently declined, decreasing by approximately 18.8% by October 7, 2026, to trade around $17.57.
2. Weakness in the Broader Biotechnology Sector.
The general market sentiment for clinical-stage biotechnology companies experienced a downturn in fiscal Q3 2026 (July to September 2026). While the biotech sector initially showed momentum, the XBI (a biotech exchange-traded fund) reached a five-year high in August 2026 before selling off into the quarter-end, closing at approximately $158. Smaller, clinical-stage biotechs, such as Scribe, generally lagged behind larger-cap and commercial-stage peers during this period of market selectivity.
Show more
Scribe Therapeutics (SCTX) stock has lost about 10% since it went public on 7/24/2026 because of the following key factors:
1. Post-IPO Price Correction Following Initial Enthusiasm.
Scribe Therapeutics (SCTX) debuted on July 24, 2026, with its stock opening at $25.00 and closing its first trading day at $21.65, representing a significant 44.33% gain from its IPO price of $15.00 per share. However, newly public stocks often experience a period of price correction after initial investor excitement. From its closing price on July 24, 2026, the stock subsequently declined, decreasing by approximately 18.8% by October 7, 2026, to trade around $17.57.
2. Weakness in the Broader Biotechnology Sector.
The general market sentiment for clinical-stage biotechnology companies experienced a downturn in fiscal Q3 2026 (July to September 2026). While the biotech sector initially showed momentum, the XBI (a biotech exchange-traded fund) reached a five-year high in August 2026 before selling off into the quarter-end, closing at approximately $158. Smaller, clinical-stage biotechs, such as Scribe, generally lagged behind larger-cap and commercial-stage peers during this period of market selectivity.
3. Mixed Fiscal Q2 2026 Earnings Report.
Scribe Therapeutics reported its fiscal Q2 2026 earnings on September 2, 2026 (during fiscal Q3 2026), for the quarter ended June 30, 2026. Although the company reported an earnings per share (EPS) of -$3.84, beating the consensus estimate of -$6.20, its quarterly revenue of $1.92 million fell below analysts' expectations of $3.10 million. Additionally, collaboration revenue significantly declined to $1.9 million in fiscal Q2 2026 from $4.9 million in the prior-year period.
4. Lack of Near-Term Clinical Data Catalysts.
As a clinical-stage biotechnology company, investor sentiment is highly sensitive to progress in drug development and clinical trials. Scribe's lead drug candidate, STX-1150, entered a Phase 1 clinical trial, but initial human data is not anticipated until the first half of 2027. The absence of significant clinical milestones or data readouts in the immediate post-IPO period contributed to a lack of catalysts for sustained upward stock movement.
5. Macroeconomic Headwinds from Interest Rate Hikes.
The Federal Reserve raised interest rates by 25 basis points in September 2026, contributing to a more cautious investment climate. Higher interest rates typically exert downward pressure on growth stocks and pre-revenue companies, like Scribe Therapeutics, whose valuations are heavily dependent on future earnings and long-term potential.
Show less
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
6/30/2026 to 10/8/2026| Return | Correlation | |
|---|---|---|
| SCTX | ||
| Market (SPY) | 3.6% | -6.7% |
| Sector (XLV) | 6.0% | 15.6% |
Fundamental Drivers
nullnull
Market Drivers
3/31/2026 to 10/8/2026| Return | Correlation | |
|---|---|---|
| SCTX | ||
| Market (SPY) | 19.3% | -6.7% |
| Sector (XLV) | 15.2% | 15.6% |
Fundamental Drivers
nullnull
Market Drivers
9/30/2025 to 10/8/2026| Return | Correlation | |
|---|---|---|
| SCTX | ||
| Market (SPY) | 17.1% | -6.7% |
| Sector (XLV) | 22.4% | 15.6% |
Fundamental Drivers
nullnull
Market Drivers
9/30/2023 to 10/8/2026| Return | Correlation | |
|---|---|---|
| SCTX | ||
| Market (SPY) | 87.3% | -6.7% |
| Sector (XLV) | 36.8% | 15.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SCTX Return | - | - | - | - | - | -19% | -19% |
| Peers Return | 9% | -62% | -18% | -59% | 14% | 1% | -84% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 14% | 108% |
Monthly Win Rates [3] | |||||||
| SCTX Win Rate | - | - | - | - | - | 25% | |
| Peers Win Rate | 25% | 27% | 45% | 30% | 48% | 56% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| SCTX Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -41% | -68% | -58% | -72% | -65% | -46% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: NTLA, BEAM, PRME, EDIT, CRBU.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/8/2026 (YTD)
How Low Can It Go
SCTX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
SCTX has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Scribe Therapeutics (SCTX)
Scribe Therapeutics (SCTX) Business Summary
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing purpose-built in vivo CRISPR technologies for disease prevention and durable therapeutic intervention. Unlike many genetic medicine companies that primarily target rare disorders, Scribe aims to address common diseases affecting millions, particularly within the cardiovascular and metabolic space. They employ a proprietary "CRISPR by Design" approach, which integrates generative artificial intelligence and machine learning with massively parallel experimental validation to engineer optimal CRISPR-based solutions for specific therapeutic applications.
The company has developed two distinct, proprietary CRISPR technologies derived from a novel CRISPR-CasX enzyme: ELXR (Epigenetic Long-Term X-Repressor) for precise, durable epigenetic silencing without altering underlying DNA, and XE (X-Editor) for specific and efficient gene editing. Their lead product candidate, STX-1150, utilizes the ELXR technology to durably lower LDL-C (bad cholesterol) by repressing PCSK9 expression, targeting a significant driver of atherosclerotic cardiovascular disease (ASCVD). STX-1150 is designed to offer long-lasting benefits without permanent genetic changes, aiming to significantly improve patient adherence and outcomes. A first-in-human clinical trial for STX-1150 is currently underway in Australia, with initial data anticipated in the first half of 2027.
Beyond STX-1150, Scribe's pipeline includes two additional programs, STX-1200 and STX-1400, which utilize their XE gene editing technology to address other key lipid drivers of ASCVD: elevated lipoprotein(a) (Lp(a)) and severely high triglycerides. Scribe aims to transform the treatment paradigm for these prevalent conditions from symptom management to population-level prevention, offering durable and scalable genetic medicines. Their primary market consists of millions of patients suffering from or at risk of cardiovascular and metabolic diseases who could benefit from more effective, long-lasting, and adherence-friendly therapeutic options than currently available standard-of-care treatments.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Scribe Therapeutics:
Scribe Therapeutics is like a Google for genetic engineering, building its own foundational CRISPR 'operating system' to develop solutions for common diseases.
Scribe Therapeutics is a cutting-edge biotech aiming to be a Pfizer for genetic medicines, creating 'one-and-done' treatments for widespread conditions like heart disease.
AI Analysis | Feedback
- STX-1150: An epigenetic silencing therapy (using ELXR technology) designed to durably lower LDL-C by repressing PCSK9 expression without altering DNA.
- STX-1200: A gene editing therapy (using XE technology) in preclinical development targeting the LPA gene to reduce elevated lipoprotein(a), a key risk factor for ASCVD.
- STX-1400: A gene editing therapy (using XE technology) in preclinical development targeting the APOC3 gene to reduce severely high triglycerides, a key risk factor for ASCVD.
- ELXR (Epigenetic Long-Term X-Repressor): A proprietary epigenetic silencing technology designed for precise, durable gene repression without altering the underlying DNA sequence.
- XE (X-Editor): A proprietary technology designed for specific and efficient gene editing.
AI Analysis | Feedback
Scribe Therapeutics (SCTX) is a clinical-stage biotechnology company. As such, it does not currently have commercialized products sold directly to individuals. Its primary "customers" and revenue sources come from strategic collaborations with other pharmaceutical companies.
The major customer companies identified are:
- Sanofi (NYSE: SNY)
- Eli Lilly and Company (NYSE: LLY)
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
- The primary risk for Scribe Therapeutics, as a clinical-stage biotechnology company, is the potential for its product candidates, particularly STX-1150, to fail in clinical trials or to not receive regulatory approval. The company anticipates reporting initial data from its first-in-human clinical trial of STX-1150 in Australia in the first half of 2027. Unfavorable results or delays in clinical development and the subsequent inability to secure regulatory clearances in major markets would significantly impede its ability to commercialize its therapies.
- Scribe Therapeutics operates in highly competitive markets, specifically the "multibillion-dollar LDL-C lowering landscape" for cardiovascular and metabolic diseases. Despite believing that current standards of care are insufficient, the company faces the challenge of competing with existing pharmaceutical therapies (small-molecule, antibody, and siRNA therapies) and other emerging genetic medicines. Achieving broad real-world impact and market adoption against established treatments with varying levels of efficacy, side effects, and adherence will be critical to its success.
- A key risk lies in the successful development, protection, and enforcement of its proprietary CRISPR technologies, including ELXR and XE, derived from a novel CRISPR-CasX enzyme. The company's business model is predicated on these "purpose-built in vivo CRISPR technologies." Any challenges to its intellectual property portfolio, such as patent disputes or the inability to obtain necessary patents, or unforeseen complexities in scaling and manufacturing these novel genetic medicines, could significantly hinder its ability to develop and commercialize its product pipeline.
AI Analysis | Feedback
Other biotechnology companies advancing in vivo gene editing or other durable genetic medicine technologies for cardiovascular and metabolic diseases, particularly those with clinical-stage programs targeting the same genes and pathways (e.g., PCSK9, Lp(a), APOC3). For example, Verve Therapeutics is developing in vivo gene editing therapies to durably lower LDL-C and Lp(a), with lead candidates already in clinical trials. The success and earlier market entry of such competing platforms could capture market share or set a high bar for efficacy and safety, potentially undermining the competitive position and market opportunity of Scribe's lead candidates, STX-1150, STX-1200, and STX-1400.
AI Analysis | Feedback
Addressable Markets for Scribe Therapeutics' Main Products
For Scribe Therapeutics' lead product candidate, STX-1150, which is designed to lower LDL-C by repressing PCSK9, the addressable market for PCSK9-based LDL-C lowering medicines currently exceeds $5 billion annually. The specific region (e.g., U.S. or global) for this market size is not explicitly stated in the provided information. For STX-1200, targeting elevated lipoprotein(a) (Lp(a)), and STX-1400, targeting severely high triglycerides by editing the LPA and APOC3 genes respectively, the company states that these programs address "key risk factors for ASCVD affecting large populations". However, a specific quantifiable market size in dollar figures for these products is not provided in the available information.AI Analysis | Feedback
Scribe Therapeutics (SCTX) has several expected drivers of future revenue growth over the next 2-3 years, primarily stemming from the advancement of its clinical pipeline and the continued realization of milestone payments from strategic collaborations.
- Advancement of Lead Product Candidate STX-1150: Scribe Therapeutics' lead product candidate, STX-1150, is currently in a first-in-human clinical trial in Australia for adults with elevated LDL-C and increased risk of atherosclerotic cardiovascular disease (ASCVD). The company anticipates reporting initial data from this trial, including safety, tolerability, and LDL-C-lowering activity, in the first half of 2027. Positive clinical trial results and subsequent progression through development stages for STX-1150, which targets a multi-billion dollar LDL-C lowering market, are expected to be a significant driver of future revenue.
- Initiation of Clinical Trials for STX-1200 and STX-1400: Scribe's next programs, STX-1200 and STX-1400, target elevated lipoprotein(a) (Lp(a)) and high triglycerides, respectively, using their X-Editor (XE) technology. The company anticipates initiating a Phase 1 clinical trial for one of these programs as early as 2027 and the other in 2028. The progression of these programs into human trials expands Scribe's pipeline into additional large and significant markets for ASCVD, creating new potential revenue streams upon successful development.
- Achievement of Milestone Payments from Strategic Collaborations: Scribe Therapeutics has established strategic collaborations with major pharmaceutical companies, including Sanofi and Eli Lilly. These partnerships involve upfront and milestone payments as programs advance. Scribe has already achieved multiple success milestones, including one for an in vivo program with Sanofi in January 2025 and a second success milestone with Eli Lilly for an in vivo program in February 2026. Scribe is eligible to receive over $1.2 billion in potential milestone payments from Sanofi and over $1.5 billion from Eli Lilly, along with future royalties. Continued progress and achievement of further research, development, regulatory, and commercial milestones within these collaborations are expected to generate significant revenue.
AI Analysis | Feedback
Share Issuance
- Scribe Therapeutics has raised approximately $150.0 million in equity financing since its founding in 2017.
- The company has undertaken only one dilutive financing in the past four years.
Inbound Investments
- The California Institute for Regenerative Medicine (CIRM) awarded Scribe Therapeutics grant funding of up to approximately $25.7 million to support the development and manufacturing of its STX-1200 and STX-1400 programs.
- The company's operating model is complemented by upfront and milestone payments from strategic collaborations, including those with Sanofi and Lilly.
Peer Outperformance in Biotechnology
null| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 13.9% | 45.7% | 94.9% | CAH 443% · MCK 376% · COR 184% |
| Health Care Services | 20 | 21.0% | 35.1% | 10.5% | HIMS 280% · RDNT 141% · DGX 79% |
| Health Care Facilities | 24 | -0.8% | 5.1% | 4.8% | THC 321% · NHC 279% · ENSG 139% |
| Managed Health Care | 8 | 22.1% | -7.9% | -0.1% | OSCR 123% · HQY 44% · ELV 12% |
| Health Care Equipment | 50 | -8.0% | -3.8% | -17.3% | POCI 11563% · UFPT 346% · GKOS 257% |
| Pharmaceuticals | 62 | -10.6% | 0.2% | -30.4% | INDV 1090% · ETON 997% · LQDA 926% |
| Health Care Supplies | 12 | 20.5% | -8.5% | -37.1% | LNTH 322% · HAE 77% · MMSI 18% |
| Life Sciences Tools & Services | 109 | -10.9% | -14.7% | -64.2% | SNWV 2286% · NTRA 243% · MEDP 219% |
| Biotechnology ← | 364 | -22.1% | -23.8% | -80.1% | CELZ 1129% · DNTH 1093% · TRVI 969% |
| Health Care Technology | 21 | -38.6% | -60.0% | -82.5% | SPOK 80% · HSTM 16% · VEEV -1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.53 |
| Mkt Cap | 0.7 |
| Rev LTM | 37 |
| Op Inc LTM | -153 |
| FCF LTM | -139 |
| FCF 3Y Avg | -166 |
| CFO LTM | -138 |
| CFO 3Y Avg | -162 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 12.6% |
| Rev Chg 3Y Avg | 49.3% |
| Rev Chg Q | -43.8% |
| QoQ Delta Rev Chg LTM | -4.9% |
| Op Inc Chg LTM | 17.3% |
| Op Inc Chg 3Y Avg | 1.0% |
| Op Mgn LTM | -477.0% |
| Op Mgn 3Y Avg | -940.1% |
| QoQ Delta Op Mgn LTM | -15.7% |
| CFO/Rev LTM | -418.8% |
| CFO/Rev 3Y Avg | -728.8% |
| FCF/Rev LTM | -421.2% |
| FCF/Rev 3Y Avg | -738.8% |
Price Behavior
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.17 | -1.22 | 0.04 | -0.10 | -3.49 | -0.58 |
| Up Beta | -11.87 | -0.03 | 0.78 | 3.09 | -5.91 | 1.23 |
| Down Beta | -7.28 | -10.27 | 1.26 | -5.06 | 0.99 | -2.54 |
| Up Capture | -16% | -63% | -92% | -31% | -14% | -1% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 11 | 24 | 26 | 26 | 26 | 26 |
| Down Capture | 558% | -29% | -29% | -17% | -9% | -5% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 11 | 18 | 21 | 21 | 21 | 21 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SCTX | |
|---|---|---|---|---|
| SCTX | -11.2% | 138.8% | 0.24 | - |
| Sector ETF (XLV) | 18.2% | 15.7% | 0.86 | 15.6% |
| Equity (SPY) | 16.7% | 13.0% | 0.91 | -6.7% |
| Gold (GLD) | 3.4% | 29.6% | 0.11 | 23.3% |
| Commodities (DBC) | 45.0% | 20.9% | 1.67 | 9.3% |
| Real Estate (VNQ) | 2.8% | 13.7% | -0.05 | 6.5% |
| Bitcoin (BTCUSD) | -31.7% | 44.2% | -0.73 | 9.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SCTX | |
|---|---|---|---|---|
| SCTX | -2.3% | 138.8% | 0.24 | - |
| Sector ETF (XLV) | 7.4% | 15.2% | 0.29 | 15.6% |
| Equity (SPY) | 14.0% | 17.1% | 0.63 | -6.7% |
| Gold (GLD) | 18.2% | 18.9% | 0.78 | 23.3% |
| Commodities (DBC) | 10.3% | 19.6% | 0.40 | 9.3% |
| Real Estate (VNQ) | 1.3% | 18.8% | -0.04 | 6.5% |
| Bitcoin (BTCUSD) | 13.7% | 52.2% | 0.43 | 9.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SCTX | |
|---|---|---|---|---|
| SCTX | -1.2% | 138.8% | 0.24 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 15.6% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | -6.7% |
| Gold (GLD) | 11.6% | 16.4% | 0.58 | 23.3% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | 9.3% |
| Real Estate (VNQ) | 4.2% | 20.7% | 0.16 | 6.5% |
| Bitcoin (BTCUSD) | 63.6% | 66.2% | 1.03 | 9.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 10/6/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 9/2/2026 | -0.3% | -4.6% | -45.7% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 1 | 1 | 1 |
| Median Positive | |||
| Median Negative | -0.3% | -4.6% | -45.7% |
| Max Positive | |||
| Max Negative | -0.3% | -4.6% | -45.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 9/2/2026 | -0.3% | -4.6% | -45.7% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 1 | 1 | 1 |
| Median Positive | |||
| Median Negative | -0.3% | -4.6% | -45.7% |
| Max Positive | |||
| Max Negative | -0.3% | -4.6% | -45.7% |
Insider Activity
Updated 7/29/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ah, Bio Fund Ii, LP | AH Bio Fund II, L.P. | Buy | 7292026 | 15.00 | 333,333 | 4,999,995 | 35,776,125 | Form | |
| 2 | Gordon, Carl L | See footnotes | Buy | 7292026 | 15.00 | 1,000,000 | 15,000,000 | 20,232,375 | Form | |
| 3 | Orbimed, Advisors Llc | See footnotes | Buy | 7292026 | 15.00 | 1,000,000 | 15,000,000 | 20,232,375 | Form | |
| 4 | Aghazadeh, Behzad | See footnotes | Buy | 7282026 | 18.25 | 7,905 | 144,266 | 56,372,206 | Form | |
| 5 | Aghazadeh, Behzad | See footnotes | Buy | 7282026 | 15.15 | 2,383,333 | 36,115,495 | 46,687,234 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ah, Bio Fund Ii, LP | AH Bio Fund II, L.P. | Buy | 7292026 | 15.00 | 333,333 | 4,999,995 | 35,776,125 | Form | |
| 2 | Gordon, Carl L | See footnotes | Buy | 7292026 | 15.00 | 1,000,000 | 15,000,000 | 20,232,375 | Form | |
| 3 | Orbimed, Advisors Llc | See footnotes | Buy | 7292026 | 15.00 | 1,000,000 | 15,000,000 | 20,232,375 | Form | |
| 4 | Aghazadeh, Behzad | See footnotes | Buy | 7282026 | 18.25 | 7,905 | 144,266 | 56,372,206 | Form | |
| 5 | Aghazadeh, Behzad | See footnotes | Buy | 7282026 | 15.15 | 2,383,333 | 36,115,495 | 46,687,234 | Form | |
| 6 | Lucas, Svetlana | Chief Business Officer | Spouse | Buy | 7272026 | 15.00 | 3,000 | 45,000 | 45,000 | Form |
| 7 | Parrot, David | Chief Financial Officer | Spouse | Buy | 7272026 | 15.00 | 1,333 | 19,995 | 19,995 | Form |
| 8 | Parrot, David | Chief Financial Officer | Child | Buy | 7272026 | 15.00 | 1,333 | 19,995 | 19,995 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.